Anticancer immunotherapy

Learn more about how we developed a synthetic vaccine using a natural product and novel chemical linker as a potential anticancer therapy.

An image of pink, purple, and blue anti-cancer cells.
Image created by the team and featured as a Chemical Science journal cover. Reproduced from Chem. Sci., 2015,6, 5120-5127 with permission from the Royal Society of Chemistry

Where did we start?

One of the most exciting new therapies to emerge in the search for anticancer therapies is to train the human immune system to recognise aberrant cells.

What did we do?

Generated a synthetic vaccine from a highly immunogenic natural product utilising a new chemical linker.

What is the impact?

This research successfully demonstrated that a synthetic vaccine has potential as a human therapy and is being further refined in ongoing research.

Research Team

Team Painter

Team Painter

Led by Professor Gavin Painter, this team is focused on developing nanomedicines, RNA-based technologies

Read more

Related publications

Latest publications 2015

2015
NKT cell-dependent glycolipid–peptide vaccines with potent anti-tumour activity

R. J. Anderson, B. J. Compton, C.-w. Tang, A. Authier-Hall, C. M. Hayman, G. W. Swinerd, et al.

Chemical Science 2015 Vol. 6 Issue 9 Pages 5120-5127

No result found